Stem cell transplantation in myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Myelodysplastic syndromes (MDS) primarily require supportive care due to patient age and limited treatment response.
• Allogeneic stem cell transplantation (SCT) is the primary curative option for younger MDS patients with HLA-identical family donors.

Purpose of the Study:

• To review the role and outcomes of allogeneic SCT in MDS management.
• To discuss factors influencing SCT success and alternative donor options.

Main Methods:

• Review of current therapeutic strategies for MDS.
• Analysis of factors impacting allogeneic SCT outcomes, including disease stage, cytogenetics, age, and blast percentage.
• Comparison of outcomes between matched sibling SCT, alternative donor SCT, and autologous SCT.

Main Results:

• Allogeneic SCT outcomes are highly variable, dependent on disease stage, cytogenetics, age, and blast percentage at transplantation.
• Optimal benefit from allogeneic SCT is achieved when performed promptly after identifying an HLA-identical sibling.
• Progression to advanced leukemia increases relapse rates and reduces transplant success.
• Delayed transplantation may be considered for select patients with refractory anemia without cytopenias or complex abnormalities.
• Transplantation using alternative donors or autologous stem cells results in inferior outcomes compared to matched sibling SCT, due to higher relapse or treatment-related mortality risks.

Conclusions:

• Allogeneic SCT from a matched sibling offers the best chance for cure in eligible MDS patients.
• Timely transplantation is crucial for maximizing success rates and minimizing relapse.
• Alternative donor sources and autologous SCT represent less optimal strategies with increased risks.